The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1994) · PubMed · Cited by 4,959
Hossfeld, D. K. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf146 · Cited by 4,625
Kanis, J. A., & Kanis, J. A. (1994) · Osteoporosis International · doi:10.1007/bf01622200 · Cited by 2,516
Diagnostic criteria and classification of mastocytosis: a consensus proposal
Valent, P., Horny, H.-P., Escribano, L., Longley, B. J., Li, C. Y., Schwartz, L. B., Marone, G., Nuñez, R., Akin, C., Sotlar, K., et al. (2001) · Leukemia Research · doi:10.1016/s0145-2126(01)00038-8 · Cited by 1,108
Self-citationNagata, H., Worobec, A. S., Oh, C. K., Chowdhury, B. A., Tannenbaum, S., Suzuki, Y., & Metcalfe, D. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10560 · Cited by 872
Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin‐Nelemans, H. C., Hamdy, N. A. T., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01807.x · Cited by 750
Self-citationLongley, B. J., Tyrrell, L., Lu, S.-Z., Ma, Y.-S., Langley, K., Ding, T.-G., Duffy, T., Jacobs, P., Tang, L. H., & Modlin, I. (1996) · Nature Genetics · doi:10.1038/ng0396-312 · Cited by 607
Longley, B. J., Metcalfe, D. D., Tharp, M., Wang, X., Tyrrell, L., Lu, S.-Z., Heitjan, D., & Ma, Y. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1609 · Cited by 552
Garcia-Montero, A. C. (2006) · Blood · doi:10.1182/blood-2006-04-015545 · Cited by 504
Self-citationSystemic Mast Cell Disease: ANALYSIS OF 58 CASES AND LITERATURE REVIEW
TRAVIS, W. D., LI, C.-Y., BERGSTRALH, E. J., YAM, L. T., & SWEE, R. G. (1988) · Medicine · doi:10.1097/00005792-198811000-00001 · Cited by 488
Cited by
Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
Valent, P., Akin, C., & Metcalfe, D. D. (2017) · Blood · doi:10.1182/blood-2016-09-731893 · Cited by 592
Mast Cells, Mastocytosis, and Related Disorders
Theoharides, T. C., Valent, P., & Akin, C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1409760 · Cited by 518
Álvarez-Twose, I., González de Olano, D., Sánchez-Muñoz, L., Matito, A., Esteban-López, M. I., Vega, A., Mateo, M. B., Alonso Díaz de Durana, M. D., de la Hoz, B., del Pozo Gil, M. D., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.02.019 · Cited by 294
Self-citationArock, M., Sotlar, K., Akin, C., Broesby-Olsen, S., Hoermann, G., Escribano, L., Kristensen, T. K., Kluin-Nelemans, H. C., Hermine, O., Dubreuil, P., et al. (2015) · Leukemia · doi:10.1038/leu.2015.24 · Cited by 290
Self-citationComprehensive mutational profiling in advanced systemic mastocytosis
Schwaab, J., Schnittger, S., Sotlar, K., Walz, C., Fabarius, A., Pfirrmann, M., Kohlmann, A., Grossmann, V., Meggendorfer, M., Horny, H.-P., et al. (2013) · Blood · doi:10.1182/blood-2013-04-496448 · Cited by 263
Diagnosis and management of anaphylaxis in precision medicine
Castells, M. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.06.012 · Cited by 242
Kristensen, T., Vestergaard, H., & Møller, M. B. (2011) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.10.004 · Cited by 208
Alvarez-Twose, I., González-de-Olano, D., Sánchez-Muñoz, L., Matito, A., Jara-Acevedo, M., Teodosio, C., García-Montero, A., Morgado, J. M., Orfao, A., & Escribano, L. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000329856 · Cited by 184
Self-citationHigh prevalence of anaphylaxis in patients with systemic mastocytosis - a single-centre experience
Gülen, T., Hägglund, H., Dahlén, B., & Nilsson, G. (2014) · Clinical & Experimental Allergy · doi:10.1111/cea.12225 · Cited by 156
Molderings, G. J., Brettner, S., Homann, J., & Afrin, L. B. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-10 · Cited by 149
The mastocytosis society survey on mast cell disorders: patient experiences and perceptions
Jennings, S., Russell, N., Jennings, B., Slee, V., Sterling, L., Castells, M., Valent, P., & Akin, C. (2014) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2013.09.004 · Cited by 143
“Medication recommendations are available and depend on MCD type.(1,2,9,18,26-29) The findings of this survey highlight a need for education of physicians in multiple disciplines, improved methods for recognition of patients with potential MCD and clear criteria for diagnosing MCD.”
BackgroundÁlvarez-Twose, I., Zanotti, R., González-de-Olano, D., Bonadonna, P., Vega, A., Matito, A., Sánchez-Muñoz, L., Morgado, J. M., Perbellini, O., García-Montero, A., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.06.020 · Cited by 142
Self-citationHigh prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis
van der Veer, E., van der Goot, W., de Monchy, J. G. R., Kluin‐Nelemans, H. C., & van Doormaal, J. J. (2012) · Allergy · doi:10.1111/j.1398-9995.2011.02780.x · Cited by 135
Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management
Pardanani, A. (2023) · American Journal of Hematology · doi:10.1002/ajh.26962 · Cited by 132
“KITD816V involvement was the most important prognostic criterion for progression of ISM to more aggressive SM subtypes.(72)”
BackgroundInfluentialWeiler, C. R., Austen, K. F., Akin, C., Barkoff, M. S., Bernstein, J. A., Bonadonna, P., Butterfield, J. H., Carter, M., Fox, C. C., Maitland, A., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.023 · Cited by 123
Jara-Acevedo, M., Teodosio, C., Sanchez-Muñoz, L., Álvarez-Twose, I., Mayado, A., Caldas, C., Matito, A., Morgado, J. M., Muñoz-González, J. I., Escribano, L., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.72 · Cited by 114
Self-citationAdult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis
Berezowska, S., Flaig, M. J., Ruëff, F., Walz, C., Haferlach, T., Krokowski, M., Kerler, R., Petat-Dutter, K., Horny, H.-P., & Sotlar, K. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.117 · Cited by 109
Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Gotlib, J., Gerds, A. T., Bose, P., Castells, M. C., Deininger, M. W., Gojo, I., Gundabolu, K., Hobbs, G., Jamieson, C., McMahon, B., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0088 · Cited by 106
Álvarez-Twose, I., Jara-Acevedo, M., Morgado, J. M., García-Montero, A., Sánchez-Muñoz, L., Teodósio, C., Matito, A., Mayado, A., Caldas, C., Mollejo, M., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.05.008 · Cited by 102
Self-citationTyrosine kinase inhibitors in the treatment of systemic mastocytosis
Ustun, C., DeRemer, D. L., & Akin, C. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.05.006 · Cited by 102
Characterization of Mast Cell Activation Syndrome
Afrin, L. B., Self, S., Menk, J., & Lazarchick, J. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.12.013 · Cited by 101
“Though not specifically designed to examine such, this study hints that survival in MCAS, as already clearly identified in indolent SM [42,43], may be equivalent to that of the general population despite the chronic morbidity of the disease.”
Pardanani, A. (2013) · Blood · doi:10.1182/blood-2013-01-453183 · Cited by 101
“9% at 25 years) were also confirmed in another study.(88) The majority of deaths in this ISM cohort were unrelated to mastocytosis; presence of KITD816V in all hematopoietic lineages was independently associated with disease progression.”
ResultSchuch, A., & Brockow, K. (2017) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2016.08.017 · Cited by 88
Avapritinib versus placebo in indolent systemic mastocytosis
Gotlib, J., Castells, M., Elberink, H. O., Siebenhaar, F., Hartmann, K., Broesby-Olsen, S., George, T. I., Panse, J., Alvarez-Twose, I., Radia, D. H., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2200339 · Cited by 81
Gülen, T., Hägglund, H., Dahlén, B., & Nilsson, G. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12410 · Cited by 75
Afrin, L. B., Butterfield, J. H., Raithel, M., & Molderings, G. J. (2016) · Annals of Medicine · doi:10.3109/07853890.2016.1161231 · Cited by 74
The international consensus classification of mastocytosis and related entities
Leguit, R. J., Wang, S. A., George, T. I., Tzankov, A., & Orazi, A. (2023) · Virchows Archiv · doi:10.1007/s00428-022-03423-3 · Cited by 65
Zanotti, R., Bonifacio, M., Lucchini, G., Sperr, W. R., Scaffidi, L., van Anrooij, B., Oude Elberink, H. N., Rossignol, J., Hermine, O., Gorska, A., et al. (2022) · Leukemia · doi:10.1038/s41375-021-01406-y · Cited by 56
The genetic basis of mast cell activation disease - looking through a glass darkly
Molderings, G. J. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.09.001 · Cited by 50
Haenisch, B., Nöthen, M. M., & Molderings, G. J. (2012) · Immunology · doi:10.1111/j.1365-2567.2012.03627.x · Cited by 48
Prevalence and risk factors for fragility fracture in systemic mastocytosis
Degboé, Y., Eischen, M., Nigon, D., Apoil, P.-A., Mailhol, C., Tournier, E., Laurent, C., Hanssens, K., Hermine, O., Paul, C., et al. (2017) · Bone · doi:10.1016/j.bone.2017.09.005 · Cited by 44
Navarro‐Navarro, P., Álvarez‐Twose, I., Pérez‐Pons, A., Henriques, A., Mayado, A., García‐Montero, A. C., Sánchez‐Muñoz, L., González‐López, O., Matito, A., Caldas, C., et al. (2023) · Allergy · doi:10.1111/all.15584 · Cited by 35
Self-citationRussell, N., Jennings, S., Jennings, B., Slee, V., Sterling, L., Castells, M., Valent, P., & Akin, C. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.07.032 · Cited by 31
Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin
Fuchs, D., Kilbertus, A., Kofler, K., von Bubnoff, N., Shoumariyeh, K., Zanotti, R., Bonadonna, P., Scaffidi, L., Doubek, M., Elberink, H. O., et al. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2020.12.022 · Cited by 30
Review and updates on systemic mastocytosis and related entities
Li, J. Y., Ryder, C. B., Zhang, H., Cockey, S. G., Hyjek, E., Moscinski, L. C., Sagatys, E., & Song, J. (2023) · Cancers · doi:10.3390/cancers15235626 · Cited by 31
“The basis for this distinction is that indolent SM patients without any of these risk factors have better progression-free survival and OS rates than other indolent SM variants [25,81,82].”
BackgroundPyatilova, P., Akin, C., Alvarez-Twose, I., Arock, M., Bonadonna, P., Brockow, K., Butterfield, J. H., Broesby-Olsen, S., Carter, M. C., Castells, M., et al. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.05.037 · Cited by 27
Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management
Pardanani, A. (2011) · American Journal of Hematology · doi:10.1002/ajh.21982 · Cited by 26
McMurray, J. C., Pacheco, C. S., Schornack, B. J., Sun, X., Brunader, J. A., Scott, A. E., Ariza, J. S., Kou, C.-T. J., Costantino, R. C., Pittman, L. M., et al. (2024) · Blood · doi:10.1182/blood.2023023347 · Cited by 11
Defining hereditary alpha-tryptasemia as a risk/modifying factor for anaphylaxis: Are we there yet?
Couto, M. L., Silva, M., Barbosa, M. J., Ferreira, F., Fragoso, A. S., & Azenha Rama, T. (2023) · European Annals of Allergy and Clinical Immunology · doi:10.23822/eurannaci.1764-1489.288 · Cited by 10
Metadata
- Authors
- Escribano, L., Álvarez-Twose, I., Sánchez-Muñoz, L., Garcia-Montero, A., Núñez, R., Almeida, J., Jara-Acevedo, M., Teodósio, C., García-Cosío, M., Bellas, C., & Orfao, A.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 124
- Issue
- 3
- Pages
- 514-521
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W1992780020
- Cited by
- 292
- References
- 43
- FWCI
- 7.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.